| Sharing Excellence |
| Video Clips |
| Book Reviews |
| News / Articles |
| HOME |
| ABOUT IDEA |
| STRATEGY AT PHASE II |
| MEASURING |
| SHARING |
| CONTACT IDEA |
| USEFUL LINKS |
| IDEA Junkie |
| IDEA Collider |
| | CLIENT AREA |
IDEA Pharma is delighted to announce the appointment of Dr. Graham Walker to its IDEAtion team. Join..
IDEA Pharma has launched the second annual Productive Innovation Index (PII), ranking 21 global phar..
For a closer look, go to: http://www.samedanltd.com/magazine/current/12 Lifecycle decisions are ..
For something that is supposed to be so clear, the terms used in Pharma strategy can cause confu..
With IDEA Pharma’s US operations securing an ever-stronger foothold, awareness is growing as t..
As IDEA Pharma widens its net across Europe, business is booming as the ‘IDEA house’..
As the ‘IDEA revolution’ continues to make waves within Pharma, more and more compan..
IDEA Pharma’s Principal IDEAtor, Mike Rea, has been voted among the PharmaVOICE Top 100 Mo..
The industry has a well-recognised problem. There is a prevailing view that developing drugs is ..
IDEA Pharma makes public its annual Productive Innovation Index (PII) With only one in four ..
IDEAtion is the process of building IDEAs. IDEAtion ensures the potential or the talent of a mol..
This is not an industry that does what is easy instead of what is best. This is not an industry ..
It used to be that those involved in the process of communication understood which part of the p..
Here’s the thing about Efficacy. It doesn’t exist. It is an abstract concept, a shorthan..
Cards on the table: no two ‘scenario planning’ projects are the same, or should be t..
IDEAtion is the process of building IDEAs. IDEAtion ensures the potential or the talent of a molecule can be thoroughly explored, and the range of strategic options and associated risks identified for investigation and assessment prior to key decision making and ‘lock-down’ of the development and marketing process. IDEAtion early in development ensures active development of the product IDEA and the creation of a roadmap for access to high value space in the market.
IDEA Sundial™ - IDEAs would be nothing without evaluation and iteration. IDEAs have edges and a defined shape - a shape that casts a specific shadow: Probability of Technical Success, Probability of Regulatory Success, Probability of Commercial Success, Time To Market, Market Value, Investment. The Sundial™ starts with a view: more shadow is worse than less shadow… It doesn’t start with an assumption that shadow in any one direction is worse than any other… You may be less worried by technical risk than by commercial risk, less concerned about time to market than cost of development… Whatever your view, we have distilled the measurement axes down to the things that really count.
When there are many strategic options that need to be evaluated, a systematic filtration process is important to prioritise the options: a bespoke dashboard with Sundials allows an at-a-glance view of the main factors in any portfolio decision.

For more on what lies behind each of the axes contact IDEA Pharma